HCV coinfection approaches zero in Spain: but cirrhosis and reinfection among gay men are still significant even with high rates of cure
26 November 2024. Related: Conference reports, Hepatitis coinfection.
Hepatitis coinfection
High rates of occult HBV in Botswana: risks from relying on HBsAg screening
1 August 2023. Related: Conference reports, Hepatitis coinfection.
First successful liver transplant from living donor with HIV/HCV coinfection: surgical video online
1 June 2023. Related: Coinfections and complications, Hepatitis coinfection.
CROI 2022: Summary of 14 key studies on HIV and liver disease
1 April 2022. Related: Conference reports, Hepatitis coinfection.
Leave no one behind: A manifesto for hepatitis C elimination
24 February 2020. Related: Hepatitis coinfection, On the web.
Tesamorelin for NAFLD in people living with HIV
13 December 2019. Related: Lipodystrophy and metabolic complications, Hepatitis coinfection.
Brazilian court suspends patent on hepatitis C medicine sofosbuvir
19 October 2018. Related: Treatment access, Hepatitis coinfection.
HCV incidence and reinfection in HIV negative gay men using PrEP in the Netherlands
24 August 2018. Related: Conference reports, Hepatitis coinfection.
MSF secures generic hepatitis C treatment at $120 per course
28 November 2017. Related: Treatment access, Hepatitis coinfection, Other news.
UK hepatitis A outbreak in gay men: shortages of HAV and HBV vaccines escalated to ‘national incident’
10 August 2017. Related: Hepatitis coinfection.
FDA approves sofosbuvir/velpatasvir/voxilaprevir (Vosevi) second-line DAA HCV treatment in the US in the US
1 August 2017. Related: Hepatitis coinfection.
FDA approves sofosbuvir/ledipasvir and sofosbuvir for children aged 12 to 17
26 June 2017. Related: Paediatric care, Hepatitis coinfection.
Cochrane review of HCV treatment misses real issues of access to care
26 June 2017. Related: Treatment access, Hepatitis coinfection.
Other selections and webcasts
24 April 2017. Related: Conference reports, Antiretrovirals, Coinfections and complications, Hepatitis coinfection, Cure-related research.
Tenofovir alafenamide (TAF) approved in US to treat hepatitis B with EU set to follow
29 November 2016. Related: Hepatitis coinfection.
2016 hepatitis C virus (HCV) update
14 July 2016. Related: Pipeline report, Hepatitis coinfection.
New HBV drugs and non-viral liver disease in HIV positive people
1 June 2016. Related: Conference reports, Hepatitis coinfection, Basic science and immunology.
High cure rates using generic hepatitis C drugs bought online: EASL supports lower cost access for Western countries
1 June 2016. Related: Conference reports, Treatment access, Hepatitis coinfection, Other news.
Studies of new generic $300 HepC combination of ravidasvir and sofosbuvir for low-income countries
1 June 2016. Related: Conference reports, Antiretrovirals, Hepatitis coinfection.
Six-week ledipasvir/sofosbuvir in HIV positive patients with acute HCV
1 June 2016. Related: Conference reports, Hepatitis coinfection.
NICE approves ombitasvir, paritaprevir, ritonavir with or without dasabuvir to treat adult HCV
1 February 2016. Related: Hepatitis coinfection.
NICE approves daclatasvir to treat adult HCV
1 February 2016. Related: Hepatitis coinfection.
Potential for generic prices for 12 weeks sofosbuvir treatment to drop below US $300 and daclatasvir to US $23
1 December 2015. Related: Conference reports, Treatment access, Hepatitis coinfection.
NICE decision on ledipasvir/sofosbuvir for chronic HCV
1 December 2015. Related: Hepatitis coinfection.
Sofosbuvir/velpatasvir submitted to US FDA for HCV genotype 1-6
1 December 2015. Related: Hepatitis coinfection.
US indication for ledipasvir/sofosbuvir expanded
1 December 2015. Related: Hepatitis coinfection.
Protection against flu but not HBV in vaccinated perinatally HIV-infected children
1 October 2015. Related: Conference reports, Paediatric care, Hepatitis coinfection.
Gilead to provide free hepatitis drugs to treat all people liviing with hepatitis C in Iceland
1 October 2015. Related: Hepatitis coinfection.
Australian doctors advice for buying generic sofosbuvir for HepC
1 October 2015. Related: Treatment access, Hepatitis coinfection.
Comprehensive review of DAA research at EASL
1 August 2015. Related: Hepatitis coinfection.
New Drugs, New Strategies: Conquering Hepatitis C with Direct-Acting Antivirals
17 July 2015. Related: Pipeline report, Hepatitis coinfection.
Sofosbuvir access: new patent challenges to sofosbuvir
1 June 2015. Related: Treatment access, Hepatitis coinfection.
Summary of the pre-conference clinical course
29 January 2015. Related: Conference reports, Hepatitis coinfection.
Hepatitis C drug access: Europe is the new Africa
29 January 2015. Related: Conference reports, Treatment access, Hepatitis coinfection.
India rejects Gilead’s patent application for sofosbuvir
29 January 2015. Related: Treatment access, Hepatitis coinfection.
Hepatitis C combination from AbbVie licensed in the UK: ombitasvir/paritaprevir/ritonavir (Viekirax) and dasabuvir (Exviera)
29 January 2015. Related: Hepatitis coinfection.
US activists called on Gilead to set a per-treatment price for sofosbuvir/ledipasvir
1 December 2014. Related: Hepatitis coinfection.
Only 10% of veterans with HCV or HCV/HIV in the US treated for HCV
1 October 2014. Related: Conference reports, Hepatitis coinfection.
Daclatasvir approved in EU for HCV genotypes 1-4
1 October 2014. Related: Hepatitis coinfection.
CHMP gives positive opinion to approve coformulated sofosbuvir/ledipasvir
1 October 2014. Related: Hepatitis coinfection.
European activists protest at meeting of European Health Ministers for access to new HCV drugs
1 October 2014. Related: Hepatitis coinfection.
US Senate investigate Gilead for sofosbuvir price: potential to bankrupt Federal healthcare and add $300 annually to every American insurance premium for the next five years
1 August 2014. Related: Hepatitis coinfection.
Hepatitis C pipeline: BONANZA! The gold rush is under way
19 July 2014. Related: Pipeline report, Hepatitis coinfection.
Global update: hepatitis C treatment activism
19 July 2014. Related: Pipeline report, Treatment access, Hepatitis coinfection.
WHO launch treatment guidelines for hepatitis C (2014)
27 May 2014. Related: Conference reports, Guidelines, Hepatitis coinfection.
Sexually transmitted HCV in HIV positive and negative gay men
27 May 2014. Related: Conference reports, Hepatitis coinfection.
Annual HCV testing and use of core antigen to reduce costs and increase diagnosis during acute HCV
27 May 2014. Related: Conference reports, Hepatitis coinfection.
EMA fast-track sofosbuvir/ledipasvir FDC for hepatitis C
27 May 2014. Related: Hepatitis coinfection.
Pharma refuses to ensure access to lifesaving hepatitis C treatment at global meeting
24 March 2014. Related: Hepatitis coinfection.
New treatments for HCV: strategies for achieving universal access
24 March 2014. Related: Hepatitis coinfection.
EASL update guidelines for treatment of hepatitis C (2013)
1 February 2014. Related: Hepatitis coinfection.
Sofosbuvir approved in the US and Europe for HCV genotypes 1-6
1 February 2014. Related: Hepatitis coinfection.
Simeprevir approved in the US
1 February 2014. Related: Hepatitis coinfection.
Fair Pricing Coalition criticises cost of new HCV drugs
1 February 2014. Related: Hepatitis coinfection.
Boehringer Ingelheim stops development of deleobuvir for HCV
1 February 2014. Related: Hepatitis coinfection.
EU recommends approval of sofosbuvir for HCV
1 December 2013. Related: Hepatitis coinfection.
Compassionate use of declatasvir with sofosbuvir for people in urgent need of HCV treatment
1 December 2013. Related: Hepatitis coinfection.
CID supplement on HCV and injecting drug users: free online issue
1 October 2013. Related: Hepatitis coinfection, Injecting drug users, On the web.
Pipeline oral HCV drugs and generic global access to DAAs: the need to mirror ARV programmes
25 July 2013. Related: Conference reports, Treatment access, Hepatitis coinfection.
Executive summary and research policy recommendations
30 June 2013. Related: Pipeline report, Antiretrovirals, Treatment strategies, Diagnostics, Hepatitis coinfection, TB coinfection.
Hepatitis C drug development catapults onward
30 June 2013. Related: Pipeline report, Hepatitis coinfection.
Low- and middle-income countries defuse hepatitis C
30 June 2013. Related: Pipeline report, Hepatitis coinfection, Virology.
Dramatic advances at CROI for HCV treatment: telaprevir, boceprevir, faldaprevir, sofosbuvir, ABT-450, ABT-267, ABT-333 and ledipasvir
29 May 2013. Related: Conference reports, Hepatitis coinfection.
HIV/HCV coinfection: early glimpses of an interferon-free future and EuroSIDA incidence data
1 December 2012. Related: Conference reports, Hepatitis coinfection.
Cure rates with pipeline HCV drugs: reports from AASLD
1 December 2012. Related: Conference reports, Hepatitis coinfection.